Melody Zhao

635 total citations
10 papers, 447 citations indexed

About

Melody Zhao is a scholar working on Neurology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Melody Zhao has authored 10 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Neurology, 4 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Melody Zhao's work include Peripheral Neuropathies and Disorders (4 papers), Multiple Sclerosis Research Studies (4 papers) and Amyotrophic Lateral Sclerosis Research (3 papers). Melody Zhao is often cited by papers focused on Peripheral Neuropathies and Disorders (4 papers), Multiple Sclerosis Research Studies (4 papers) and Amyotrophic Lateral Sclerosis Research (3 papers). Melody Zhao collaborates with scholars based in Canada, Switzerland and Germany. Melody Zhao's co-authors include Rebekah van Bruggen, Jeehye Park, Dieter A. Häring, Chris Cameron, Nicholas Adlard, Evelyn Worthington, Luisa Klotz, Imtiaz A. Samjoo, Kirill Zaslavsky and James Ellis and has published in prestigious journals such as Nature Communications, Nature Neuroscience and FEBS Letters.

In The Last Decade

Melody Zhao

10 papers receiving 441 citations

Peers

Melody Zhao

MB

NEURO

PFM

GENET

Sarah MacKinnon United States

Estefanía Torres-Vega Spain

Xueping Zheng China

Christopher Adams United States

Noriko Miyake Japan

Monize Lazar Brazil

Peter Körtvélyessy Germany

Miriam S. Reuter Germany

Wade Clapp United States

Sheena Chew United States

Sarah MacKinnon United States

Melody Zhao

448 ×2.0

MB

84 ×0.6

NEURO

146 ×1.1

PFM

299 ×3.5

GENET

21 ×0.3

GENET

Citations per year, relative to Melody Zhao Melody Zhao (= 1×) peers Sarah MacKinnon

Countries citing papers authored by Melody Zhao

Since Specialization

Citations

This map shows the geographic impact of Melody Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melody Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melody Zhao more than expected).

Fields of papers citing papers by Melody Zhao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melody Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melody Zhao. The network helps show where Melody Zhao may publish in the future.

Co-authorship network of co-authors of Melody Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Melody Zhao. A scholar is included among the top collaborators of Melody Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melody Zhao. Melody Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Zhao, Melody, et al.. (2023). Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review. Targeted Oncology. 18(3). 327–358. 7 indexed citations

2.

Samjoo, Imtiaz A., Luisa Klotz, Gavin Giovannoni, et al.. (2022). Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 66. 104031–104031. 10 indexed citations

3.

Zhao, Melody, Nozomu Tanaka, Izumi Kawachi, et al.. (2022). Systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis. Clinical and Experimental Neuroimmunology. 13(4). 234–245. 2 indexed citations

4.

Samjoo, Imtiaz A., Evelyn Worthington, Melody Zhao, et al.. (2021). Efficacy classification of modern therapies in multiple sclerosis. Journal of Comparative Effectiveness Research. 10(6). 495–507. 80 indexed citations

5.

Zhao, Melody, Claudia Arndt, Jialu Xu, et al.. (2020). Knockdown of genes involved in axonal transport enhances the toxicity of human neuromuscular disease‐linked MATR3 mutations in Drosophila. FEBS Letters. 594(17). 2800–2818. 9 indexed citations

6.

Samjoo, Imtiaz A., Evelyn Worthington, Melody Zhao, et al.. (2020). Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. Journal of Comparative Effectiveness Research. 9(18). 1255–1274. 45 indexed citations

7.

Bruggen, Rebekah van, Melody Zhao, Claudia Arndt, et al.. (2020). Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS. Nature Communications. 11(1). 5304–5304. 31 indexed citations

8.

Zaslavsky, Kirill, Deivid C. Rodrigues, Éric Deneault, et al.. (2019). SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons. Nature Neuroscience. 22(4). 556–564. 122 indexed citations

9.

Zhao, Melody, et al.. (2018). RNA-Binding Proteins in Amyotrophic Lateral Sclerosis.. Europe PMC (PubMed Central). 41(9). 818–829. 95 indexed citations

10.

Rodrigues, Deivid C., Dae Sung Kim, Guang Yang, et al.. (2016). MECP2 Is Post-transcriptionally Regulated during Human Neurodevelopment by Combinatorial Action of RNA-Binding Proteins and miRNAs. Cell Reports. 17(3). 720–734. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact